Surgery Partners price target lowered to $42 from $43 at Citi

Citi lowered the firm’s price target on Surgery Partners to $42 from $43 and keeps a Buy rating on the shares post the Q4 report. The quarter contained “noise” from lower general and administrative expenses quarter-over-quarter, suggesting a lower-quality Q4, although the difference was incentive comp dynamics, the analyst tells investors in a research note. The firm is a buyer on the post-earnings share weakness, saying “comps get cleaner” moving through 2024.